1338221-17-2

Upstream product

• 1178890-01-1 2-amino-3-bromo-5-[p-(t-butyldimethylsilyloxy)phenyl]-1,4-pyrazine 
• 28611-39-4 4-(dimethylamino)benzene-boronic acid 
• 549503-20-0 5-(p-tert-butyldimethylsilyloxyphenyl)-2-amino-1,4-pyrazine 
• 159191-56-7 (4-((tert-butyldimethylsilyl)oxy)phenyl)boronic acid 
• 106-41-2 4-bromo-phenol 
• 67963-68-2 t-butyldimethylsilyl-4-bromophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1178890-03-3 2-amino-3-(4-N,N-dimethylaminophenyl)-5-(4-hydroxyphenyl)-1,4-pyrazine 
• 1338221-18-3 2-[4-(tert-butyldimethylsilyloxy)phenyl]-N-[5-{4-(tert-butyldimethylsilyloxy)phenyl}-3-{4-(dimethylamino)phenyl}pyrazin-2-yl]acetamide 
• 1338220-49-7 N-[3-{4-(dimethylamino)phenyl}-5-(4-hydroxyphenyl)pyrazin-2-yl]-2-(4-hydroxyphenyl)acetamide 

Relevant academic research and scientific papers

COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES

Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the

COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES

Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide.

In vitro and in vivo studies of 6,8-(diaryl)imidazo[1,2-a]pyrazin-3(7H)-ones as new antioxidants

A series of 5-aryl and 3,5-diaryl-2-amino-1,4-pyrazines and the derived imidazopyrazinones has been synthesized to study the chemical oxidative degradation of the bicyclic systems in vitro. Imidazopyrazinones mainly degraded following two independent pathways producing their precursors, namely aminopyrazines, and the corresponding amidopyrazines, respectively. Despite the fact that there is no influence of the substituent of the 3-aryl group on the ratio of the products aminopyrazine/amidopyrazine, diarylimidazopyrazinones and diarylaminopyrazines are good antioxidants in vivo. They protected against microvascular damages in ischemia/reperfusion with similar efficiencies.